Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical injectable BL-M05D1 (Claudin18.2 ADC) program for CLDN18.2 positive advanced gastric cancer or gastroesophageal adenocarcinoma (GC/GEJC) patients who have previously been treated with first-line standards has been included in the list of breakthrough treatments by the Drug Evaluation Center of the State Drug Administration (“Drug Evaluation Center”).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.